FibroBiologics faces Nasdaq delisting after bid price stays below $1
FBLG•Nasdaq delisting notice after bid price rule breach
FibroBiologics received a Nasdaq staff determination on July 22, 2026, citing noncompliance with the $1 minimum bid price rule.
Shares closed below $1 for 30 consecutive sessions from June 8, 2026 through July 21, 2026, triggering a delisting decision.
Nasdaq denied the usual 180-day cure period because the company completed a reverse stock split within the past year.
Delisting is set for July 31, 2026 unless an appeal is filed by July 29, 2026; a timely hearing request stays the suspension.
The company plans to appeal and present a plan to regain compliance, though continued listing is not assured.
